A striking rise in ADHD prescriptions among Canadian women has sparked concerns about the quality of diagnoses and the long-term health implications. This surge, particularly in Ontario, has led to a significant increase in stimulant medication use, with potential consequences that cannot be ignored.
According to a study published in JAMA Network Open, new stimulant prescriptions in Ontario have skyrocketed by a staggering 157% between 2015 and 2023. The annual growth rate, initially at a steady 7% from 2015 to 2019, accelerated to an alarming 28% annually once COVID-19 lockdowns began in 2020.
But here's where it gets controversial... the increase in stimulant use is most prominent among adult women. For females aged 25 to 44, stimulant use rose by a whopping 421%, and for those aged 18 to 24, it increased by approximately 369%. Daniel Myran, the first author of the study, highlighted that in 2023, more females aged 25 to 44 had used stimulants in the past year compared to males.
So, what's behind this gender disparity? Myran suggests that earlier diagnostic criteria focused on hyperactivity, a symptom more commonly associated with males. However, recent attention has shifted towards women's inattentive symptoms, such as difficulty focusing and setting priorities. This shift in diagnostic focus may have contributed to the surge in prescriptions among adult women.
Children have also experienced an increase in stimulant use, although not as dramatic as in adults. New prescriptions rose by 191% for girls aged 10 to 14 and 67.5% for boys in the same age group.
CP24 attributes this rise to several factors, including increased screen time, greater public awareness and acceptance of ADHD, and the identification of previously undiagnosed individuals.
During the pandemic, private virtual care clinics offering ADHD assessments expanded rapidly, making diagnosis more accessible. While this lowered barriers to diagnosis, it also raised concerns about misdiagnosis and overdiagnosis. Daniel Myran, a family practice physician, shared his experience of encountering patients with inaccurate ADHD labels, which prompted the study. He warns that an incorrect diagnosis can lead to pursuing the wrong treatment, potentially hindering the chance of receiving the right treatment for the actual condition.
But here's the catch... these drugs are not without their risks. Stimulant side effects can include appetite loss, sleep problems, and anxiety. Long-term use may also increase blood pressure and the risk of stroke and heart attacks.
Myran emphasizes that when severe ADHD symptoms hinder individuals from participating in school or work, the benefits of treatment may outweigh the risks. However, as prescribing broadens to include a wider range of individuals, the risk-benefit ratio may become less favorable.
This pattern is not limited to Ontario. Heather Palis, a senior scientist at the BC Centre for Disease Control, found similar trends in her study in British Columbia. The fastest growth in ADHD diagnoses was among females, with an estimated rate of increase more than twice that of males during the pandemic.
Palis highlights the need for services to support this growing population, including prescribers who can monitor patients for adverse effects.
So, what's your take on this? Do you think the rise in ADHD prescriptions among women is a cause for concern, or is it a positive step towards better recognition and treatment of this condition? Share your thoughts in the comments below!
